Particularly in bladder and certain lung cancers, but also in Non-Hodgkin Lymphoma (NHL) tumours, there is a relatively high prevalence (up to 20%) of tumours with a loss of function mutation in either p300 or CBP.
There is pre-clinical evidence that the tumours are then dependent on the non-mutated paralogue, and thus sensitive to an inhibitor of both p300 and CBP.
Inobrodib inhibits both p300 and CBP
Tumours with a mutation in one or other twin (paralogue) proteins, are likely to be more susceptible to CellCentric's drug.
Over-expression of MYC and AR
Additionally, given that inobrodib is known to significantly impact AR and MYC expression, tumours that are driven by these factors are also being examined. This represents specific populations in a wide range of tumour types, including breast cancers.